Clinical trial
Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a…
NCT00137917 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00137917 |
|---|---|
| Title | Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs |
| Official title | A Primary Vaccination Study to Evaluate Immunogenicity, Safety and Reactogenicity of 3 Doses of GSK Biologicals/Finlay's Meningococcal B Candidate Vaccine Given Intramuscularly Using Either 0-2-4 Month or 0-1-6 Month Schedule to Healthy Subjects Aged 12-18 Years |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Infections, Meningococcal |
| Intervention type | Biological |
| Interventions | Meningococcal serogroup B vaccine |
| Enrollment | 478 |
| Start date | Jul 1, 2002 |
| Primary completion | Jun 1, 2003 |
| Completion | Jun 1, 2003 |
| First posted | Aug 30, 2005 |
| Last update posted | Sep 16, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: